Cautionary Note on Forward-looking Statements

This presentation contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, market position and business strategy, and the anticipated separation of the Company’s Consumer Health business. The viewer is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies; the Company’s ability to satisfy the necessary conditions to consummate the separation of the Company’s Consumer Health business on a timely basis or at all; the Company’s ability to successfully separate the Company’s Consumer Health business and realize the anticipated benefits from the separation; the New Consumer Health Company’s ability to succeed as a standalone publicly traded company; and risks related to the impact of the COVID-19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays and cancellations of medical procedures, supply chain disruptions and other impacts to the business, or on the Company’s ability to execute business continuity plans, as a result of the COVID-19 pandemic. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 2, 2022, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this presentation speaks only as of the date of this presentation. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

Cautionary Note on Non-GAAP Financial Measures

This presentation refers to certain non-GAAP financial measures. These non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.

A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the Company’s website at www.investor.jnj.com/sales-earnings.cfm.
Global environmental sustainability

Paulette Frank
Chief Sustainability Officer
Our approach to environmental sustainability

Decarbonize our operations and value chain

Deliver sustainable products and solutions

Advance environmental health equity
Health for Humanity 2025 Goals  |  Environmental Health

100% renewable electricity in our operations globally by 2025

On track

Progress: 52% of electricity is produced or procured from renewable sources

Carbon neutrality for our operations by 2030

On track

Progress: 34% reduction in carbon emissions vs. 2016 baseline

Reduce upstream value chain (Scope 3) emissions 20% by 2030*

On track

Progress: Engaging suppliers through new programs, including Energize and Onwards

2021 Achievements

Joined the Race to Zero with an ambition to reach net zero emissions by 2045

Earned A-rating from CDP for climate action for the 4th year in a row and received the highest possible rating for supplier engagement for the 5th year in a row

*From 2016 baseline
We are delivering sustainable products and solutions across our business segments

**Pharmaceutical**
Replaced plastic trays used in our TREMFYA® One Press with recyclable packaging. Our aim is to convert all our self-injectable device platforms by 2025.

**MedTech**
Partnering with hospitals to recycle metal and plastic components from Ethicon single-use instruments. The initiative is expanding to several countries.

**Consumer Health**
Launched new recyclable LISTERINE® bottles made with up to 50% recycled plastic with the goal to use only 100% recycled plastic by 2030.
We are working with partners to accelerate our progress and amplify our impact

Supporting Beyond the Megawatt to create a resilient, equitable and sustainable energy system

Participating in Action Collaborative to Decarbonize the U.S. Health Sector to align on goals and actions

Founding member of a public-private partnership convened by NHS (UK) to address shared challenges

Partnering to advance health equity by building climate resilience in more than 100 U.S. healthcare clinics
Our vision for a sustainable future is one in which healthy lives and a healthy planet are within reach of all people.